NCT06529406View on ClinicalTrials.gov

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2029

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Ozanimod

De-escalation of anti-CD20 treatment using ozanimod.

Trial Locations (3)

44195

RECRUITING

Cleveland Clinic, Cleveland

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

89106

RECRUITING

Cleveland Clinic, Las Vegas

All Listed Sponsors
lead

University of Colorado, Denver

OTHER